Idéal Investisseur Galteron Galteron
Français English
CAC 40 : Market open
8 197,50 pts
-0.23%


Last updated : 18/11/2026 - 13h38
🏠 Home   ➤    Stock news

Sartorius Stedim Biotech Shares Break Through €228.40 for the Third Time

The bioprocessing specialist gains in mid-session, in a nearly stable Paris market. The stock returns to a technical threshold it had already approached earlier this week, while analysts continue to closely monitor its valuation.


Sartorius Stedim Biotech Shares Break Through €228.40 for the Third Time

A €228.40 Threshold Breached After Several Attempts, With €230 in Sight

Shares of Sartorius Stedim Biotech gain 1.87% to €228.40, placing the stock among the strongest gainers in the SBF 120, while the index is nearly flat.

During the session, the stock moved above its €228.40 resistance and is holding just above that level. The level had already been touched on November 12, before a 2% pullback, and then approached on the 16th. This is therefore a third attempt within a few sessions.

The next level is at €230. The gap with the moving averages has widened: the price is 2.58% above the MM20 (€222.65) and nearly 24% above the MM200 (€184.51), after a 25.8% gain over three months.

Solid Nine-Month Results and Confirmed Targets Behind the Stock's Rebound

When the first nine months of 2026 were published on October 22, the group had confirmed its annual targets. Free cash flow rose 58.5%, and operating activity grew 7.8% at constant exchange rates. Management then stated that momentum across all regions clearly strengthened its confidence for the end of the year.

Among the risks cited on that occasion was the evolution of trade policy, which plays an increasingly important role in the sector.

According to the consensus of recorded analysts, the stock trades at about 45.9 times earnings for the current fiscal year and 37.7 times those of the following year. Analyst opinions therefore remain a benchmark for assessing the valuation, as the price tests €230.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Diagnostic et services de laboratoire › Outils des sciences de la vie / bioproduction


Context

Period
  • Period: T3 2026
Key reported figures
  • Revenue: 762,1 millions d'euros
  • Quarterly revenue: 762,1 millions d'euros
  • Revenue growth: 8 %
  • Net income: 95,5 millions d'euros

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours